Group 1 - The core product, Duanjin Detox Capsule, is developed based on folk remedies for treating opioid addiction and preventing relapse, with key ingredients including Kouwen and Yangjinhua [2] - The clinical trial results indicate that the product met its expected goals, showing significant efficacy in detoxification and relapse prevention, with a one-year relapse rate potentially as low as 30% [2] - The company reported high relapse rates among heroin users, with 77.7% relapsing within three months and over 95% within six months after detoxification [2] Group 2 - The company has applied for breakthrough therapy designation for the product, with an expected approval result around September 20, 2023, following a 45-working-day review period [2] - There are uncertainties regarding the approval from the National Medical Products Administration for market launch, and the company will actively promote the research project in accordance with national regulations [3]

Core Viewpoint - The article discusses the Phase I clinical trial results of Yifan Pharmaceutical's "Duanjin Detox Capsule," which is designed for opioid addiction treatment. Despite achieving expected results, the company's stock price fell over 2% on the announcement day [3]. Group 1: Product Overview - The Duanjin Detox Capsule is a traditional Chinese medicine capsule developed based on folk experience, primarily composed of "Gouwen" and "Yangjinhua." It aims to treat opioid addiction and prevent relapse [3]. - The product is indicated for clearing toxins and calming the mind, specifically targeting symptoms of opioid substance addiction [3]. Group 2: Clinical Trial Results - According to Yifan Pharmaceutical, the relapse rate for heroin and other opioid dependents is significantly high, with a 77.7% relapse rate within three months and over 95% within six months after detoxification [3]. - The company claims that the Duanjin Detox Capsule shows promising efficacy in detoxification treatment for various levels of heroin dependence, with a one-year relapse rate potentially as low as 30% [3]. Group 3: Regulatory Status - Yifan Pharmaceutical applied for breakthrough therapy designation for the product on July 15, 2025, and expects to receive approval results around September 20, 2025, based on a 45-working-day review period [3]. - The company acknowledges that there are uncertainties regarding the approval from the National Medical Products Administration and commits to actively advancing the project in compliance with national regulations [4].